Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 12

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

A systematic comparison of hepatobiliary adverse drug reactions in FDA and EMA drug labeling reveals discrepancies

Wu, Yue, Xiao, Wenzhong, Tong, Weida, Borlak, Jürgen, Chen, Minjun · 2022 · Drug Discovery Today

Abstract

Drug labeling informs physicians and patients on the safe and effective use of medication. However, recent studies suggested discrepancies in labeling of the same drug between different regulatory agencies. Here, we evaluated the hepatic safety information in labeling for 549 medications approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Limited discrepancies were found regarding risk for hepatic adverse drug reactions (ADRs) (8.7% in hepatic ADR warnings and 21.3% in contraindication for liver disease), while caution should be exercised over drugs with inconsistencies in contraindications for liver disease and evidence for hepatotoxicity (4.9%). Most discrepancies were attributable to less-severe hepatic events and low-frequency hepatic ADR reports and had limited implication on clinical outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.drudis.2021.09.009

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 31

  1. Watson, 2009, The New Food and Drug Administration Drug Package Insert: implications for patient safety and clinical care, Anesthesia Analgesia, 108, 211, 10.1213/ane.0b013e31818c1b27 · DOI
  2. McMahon, 2014, The package insert: who writes it and why, what are its implications, and how well does medical school explain it?, J Psychiatric Pract, 20, 284, 10.1097/01.pra.0000452565.83039.20 · DOI
  3. Kashoki, 2020, A comparison of EMA and FDA decisions for new drug marketing applications 2014–2016: concordance, discordance, and why, Clin Pharmacol Ther, 107, 195, 10.1002/cpt.1565 · DOI
  4. Bjornsson, 2015, Discrepancies in liver disease labeling in the package inserts of commonly prescribed medications, Gastroenterology, 148, 269, 10.1053/j.gastro.2014.12.007 · DOI · Paper page
  5. DeMuro, 2013, Assessment of PRO label claims granted by the FDA as compared to the EMA (2006–2010), Value Health, 16, 1150, 10.1016/j.jval.2013.08.2293 · DOI
  6. Nieminen, 2005, Differences in product information of biopharmaceuticals in the EU and the USA: implications for product development, Eur J Pharm Biopharm, 60, 319, 10.1016/j.ejpb.2005.01.013 · doi:10.1016/j.ejpb.2005.01.013
  7. Ernst, 2001, Drug-related morbidity and mortality: updating the cost-of-illness model, J Am Pharm Assoc, 41, 192
  8. Johnson, 1997, Drug-related morbidity and mortality and the economic impact of pharmaceutical care, Am J Health-Syst Pharm, 54, 554, 10.1093/ajhp/54.5.554 · DOI · Paper page
  9. Lazarou, 1998, Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies, JAMA, 279, 1200, 10.1001/jama.279.15.1200 · DOI · Paper page
  10. Murphy, 2006, ‘Black box’ 101: how the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk, J Allergy Clin Immunol, 117, 34, 10.1016/j.jaci.2005.10.031 · DOI
  11. Suzuki, 2015, Comedications alter drug-induced liver injury reporting frequency: data mining in the WHO VigiBase™, Regulat Toxicol Pharmacol: RTP, 72, 481, 10.1016/j.yrtph.2015.05.004 · DOI · Paper page
  12. Hoyumpa, 1982, Major drug interactions: effect of liver disease, alcohol, and malnutrition, Annu Rev Med, 33, 113, 10.1146/annurev.me.33.020182.000553 · DOI
  13. Franz, 2013, Dose adjustment in patients with liver cirrhosis: impact on adverse drug reactions and hospitalizations, Eur J Clin Pharmacol, 69, 1565, 10.1007/s00228-013-1502-z · doi:10.1007/s00228-013-1502-z
  14. Frye, 2006, Liver disease selectively modulates cytochrome P450–mediated metabolism, Clin Pharmacol Ther, 80, 235, 10.1016/j.clpt.2006.05.006 · DOI · Paper page
  15. Chalasani, 2016, Drug-induced liver injury in patients with preexisting chronic liver disease in drug development: how to identify and manage?, Gastroenterology, 151, 1046, 10.1053/j.gastro.2016.10.010 · DOI
  16. Lewis, 2002, The rational use of potentially hepatotoxic medications in patients with underlying liver disease, Expert Opin Drug Saf, 1, 159, 10.1517/14740338.1.2.159 · DOI
  17. Russo, 2004, Are patients with elevated liver tests at increased risk of drug-induced liver injury?, Gastroenterology, 126, 1477, 10.1053/j.gastro.2004.03.030 · DOI
  18. Fontana, 2009, Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct, Drug Saf, 32, 55, 10.2165/00002018-200932010-00005 · DOI · Paper page
  19. Björnsson, 2016, Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports, Hepatology, 63, 590, 10.1002/hep.28323 · DOI · Paper page
  20. Liang, 2002, FDA use of the black box warning: time for reevaluation as a safety tool, J Clin Anesth, 14, 561, 10.1016/S0952-8180(02)00444-0 · DOI
  21. Yarrington, 2019, Impact of FDA black box warning on fluoroquinolone and alternative antibiotic use in southeastern US hospitals, Infect Control Hosp Epidemiol, 40, 1297, 10.1017/ice.2019.247 · doi:10.1017/ice.2019.247
  22. McCormack, 2005, Metformin’s contraindications should be contraindicated, Can Med Assoc J, 173, 502, 10.1503/cmaj.045292 · DOI
  23. Zaremba, 2019, Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?, J ImmunoTher Cancer, 7, 10.1186/s40425-019-0626-9 · DOI
  24. Björnsson, 2016, Hepatotoxicity by drugs: the most common implicated agents, Int J Mol Sci, 17, 224, 10.3390/ijms17020224 · DOI · Paper page
  25. Chalasani, 2015, Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study, Gastroenterology, 148, 1340, 10.1053/j.gastro.2015.03.006 · DOI · Paper page
  26. Suzuki, 2010, Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBaseTM, Drug Saf, 33, 503, 10.2165/11535340-000000000-00000 · DOI · Paper page
  27. Rockey, 2010, Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method, Hepatology, 51, 2117, 10.1002/hep.23577 · DOI · Paper page
  28. Hey-Hadavi, 2021, Overview of causality assessment for drug-induced liver injury (DILI) in clinical trials, Drug Saf, 44, 619, 10.1007/s40264-021-01051-5 · DOI
  29. Hazell, 2006, Under-reporting of adverse drug reactions: a systematic review, Drug Saf, 29, 385, 10.2165/00002018-200629050-00003 · DOI · Paper page
  30. Alatawi, 2017, Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS), Expert Opin Drug Saf, 16, 761, 10.1080/14740338.2017.1323867 · DOI · Paper page
  31. Tomlin, 2012, Methods for retrospective detection of drug safety signals and adverse events in electronic general practice records, Drug Saf, 35, 733, 10.1007/BF03261970 · DOI

Cited by

See all 12

Metadata

Authors
Wu, Y., Xiao, W., Tong, W., Borlak, J., & Chen, M.
Venue
Drug Discovery Today
Publisher
Elsevier BV
Published
2022-01
Volume
27
Issue
1
Pages
337-346
ISSN
1359-6446
Cited by
12
References
3
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
U.S. Food and Drug Administration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A systematic comparison of hepatobiliary adverse drug reactions in FDA and EMA drug labeling reveals discrepancies. https://app.cochat.ai/papers/10.1016/j.drudis.2021.09.009
The paper
Wu, Y., Xiao, W., Tong, W., Borlak, J., & Chen, M. (2022). A systematic comparison of hepatobiliary adverse drug reactions in FDA and EMA drug labeling reveals discrepancies. Drug Discovery Today. https://doi.org/10.1016/j.drudis.2021.09.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.